Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956414 | 0.80 | SIGMAR1 (0.40) | SMN1; SMN2KMT2AMEN1HSD17B10LMNA | |
| SCHEMBL22581246 | 0.80 | CYP1A2 (0.34) | SMN1; SMN2 | |
| SCHEMBL30415271 | 0.78 | GLA (0.49) | SMN1; SMN2GLAKMT2AMEN1HSD17B10 | |
| SCHEMBL15812850 | 0.78 | HRH3 (0.33) | — | |
| SCHEMBL26579714 | 0.77 | GLA (0.52) | SMN1; SMN2GLAKMT2AMEN1HSD17B10 | |
| SCHEMBL28413813 | 0.77 | GLA (0.55) | SMN1; SMN2GLAKMT2AMEN1HSD17B10 | |
| SCHEMBL12536191 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 | |
| SCHEMBL19986235 | 0.73 | SMN1; SMN2 (0.47) | SMN1; SMN2GLAKMT2AMEN1HSD17B10 | |
| SCHEMBL14025174 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL12454198 | 0.73 | SMN1; SMN2 (0.42) | SMN1; SMN2GLAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289430-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289429-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A1 | SMN1; SMN2 4871/4885GLA 1412/4885KMT2A 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.